MediciNova, Inc.
4350 La Jolla Village Drive, Suite 950
San Diego
California
92122
United States
Tel: 858-373-1500
Fax: 858-373-7000
Website: http://www.medicinova.com/
Email: info@medicinova.com
334 articles about MediciNova, Inc.
-
MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)
3/9/2020
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that it plans to initiate development of MN-166 for severe pneumonia and acute respiratory distress syndrome.
-
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan
2/17/2020
LA JOLLA, Calif., Feb. 17, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH). Once issued, th
-
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
1/27/2020
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF).
-
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia
12/4/2019
Highlights of the presentation, entitled "Interaction of ALS Progression and the Efficacy of MN‑166”, which will be presented by Kazuko Matsuda, M.D. Ph.D. M.P.H., Chief Medical Officer of MediciNova, Inc.
-
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
10/28/2019
MediciNova, Inc. announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-166 for the treatment of amyotrophic lateral sclerosis
-
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan
10/23/2019
MediciNova, Inc. announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
-
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
4/15/2019
MediciNova, Inc. announced that the U.S. Food and Drug Administration has completed its review of the protocol and determined that MediciNova may proceed with a Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis.
-
Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
-
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
-
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
-
Investors in La Jolla, Calif.-based MediciNova are celebrating this morning as company shares are up more than 18 percent following the early completion of a mid-stage non-alcoholic steatohepatitis trial.
-
MediciNova’s Drug Flunks Phase II Trial
3/29/2018
MediciNova announced that its Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence. -
MediciNova Announces Closing of Underwritten Public Offering of Common Stock
2/13/2018
In addition, MediciNova has granted the underwriters a 30-day option to purchase up to an additional 662,983 shares of common stock at the public offering price, less underwriting discounts and commissions.
-
MediciNova Announces Proposed Underwritten Public Offering of Common Stock
2/8/2018
The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
-
MediciNova Announces Pricing of Underwritten Public Offering of Common Stock
2/8/2018
All of the shares of common stock to be sold in the offering are being offered by MediciNova.
-
MediciNova Appoints Hideki Nagao to its Board of Directors
11/10/2017
Mr. Nagao complements the MediciNova Board with 40 years of experience in finance and corporate law with financial institutions in Japan.
-
MediciNova Announces Collaboration With the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder
11/10/2017
The proposed clinical trial will evaluate MN-166 (ibudilast) as a potential treatment for individuals diagnosed with MA use disorder with or without post-traumatic stress disorder.
-
MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS ...
10/30/2017
The drug achieved a statistically significant 48% reduction in whole brain atrophy with a favorable safety and tolerability profile. -
MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase IIb Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability
10/26/2017
The study was conducted by the NeuroNEXT network with funding from the NIH National Institute of Neurological Diseases and Stroke, the National Multiple Sclerosis Society, and MediciNova.
-
MediciNova, Inc. Announces The Completion Of Enrollment In The Phase II Clinical Trial Of MN-166 (Ibudilast) In Methamphetamine Dependence
9/19/2017